// App-Quantinova.ai

2624 : A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

Researchers

Presenter

  • Manish R. Patel

Principal Investigators

  • Aung Naing

  • Howard A. Burris III

  • Chia-Chi Lin

  • Giuseppe Curigliano

  • Fiona Thistlethwaite

  • Anna Rachel Minchom

  • Paolo Antonio Ascierto

  • Filippo G. De Braud

  • Michael Cecchini

  • Wouter Hanekom

  • Richard C.A Sainson

  • Rosamund J Wilson

  • Sonia Quaratino

Medical Centers

  • Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, National Taiwan University Hospital, Taipei, Taiwan, Istituto Europeo di Oncologia, Milan, IRCCS and University of Milano, Milan, Italy

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Italy

  • Yale Cancer Center, New Haven, CT, Kymab Ltd., Cambridge, United Kingdom

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03829501

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved